|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CRISPLD1 |
Gene summary for CRISPLD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CRISPLD1 | Gene ID | 83690 |
| Gene name | cysteine rich secretory protein LCCL domain containing 1 | |
| Gene Alias | CRISP-10 | |
| Cytomap | 8q21.13 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9H336 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83690 | CRISPLD1 | LZE4T | Human | Esophagus | ESCC | 6.03e-06 | 2.81e-01 | 0.0811 |
| 83690 | CRISPLD1 | P2T-E | Human | Esophagus | ESCC | 6.04e-13 | 2.49e-01 | 0.1177 |
| 83690 | CRISPLD1 | P5T-E | Human | Esophagus | ESCC | 3.68e-19 | 4.42e-01 | 0.1327 |
| 83690 | CRISPLD1 | P8T-E | Human | Esophagus | ESCC | 1.24e-04 | 1.17e-01 | 0.0889 |
| 83690 | CRISPLD1 | P10T-E | Human | Esophagus | ESCC | 7.90e-21 | 4.22e-01 | 0.116 |
| 83690 | CRISPLD1 | P11T-E | Human | Esophagus | ESCC | 3.41e-03 | 3.75e-01 | 0.1426 |
| 83690 | CRISPLD1 | P12T-E | Human | Esophagus | ESCC | 7.77e-25 | 6.94e-01 | 0.1122 |
| 83690 | CRISPLD1 | P16T-E | Human | Esophagus | ESCC | 4.90e-52 | 9.64e-01 | 0.1153 |
| 83690 | CRISPLD1 | P20T-E | Human | Esophagus | ESCC | 1.16e-04 | 5.45e-02 | 0.1124 |
| 83690 | CRISPLD1 | P22T-E | Human | Esophagus | ESCC | 7.83e-09 | 1.22e-01 | 0.1236 |
| 83690 | CRISPLD1 | P23T-E | Human | Esophagus | ESCC | 4.12e-04 | 8.39e-02 | 0.108 |
| 83690 | CRISPLD1 | P27T-E | Human | Esophagus | ESCC | 1.95e-02 | 1.36e-01 | 0.1055 |
| 83690 | CRISPLD1 | P31T-E | Human | Esophagus | ESCC | 5.29e-10 | 1.99e-01 | 0.1251 |
| 83690 | CRISPLD1 | P32T-E | Human | Esophagus | ESCC | 9.33e-07 | 2.27e-01 | 0.1666 |
| 83690 | CRISPLD1 | P37T-E | Human | Esophagus | ESCC | 4.49e-02 | 1.52e-01 | 0.1371 |
| 83690 | CRISPLD1 | P44T-E | Human | Esophagus | ESCC | 3.94e-04 | 1.80e-01 | 0.1096 |
| 83690 | CRISPLD1 | P47T-E | Human | Esophagus | ESCC | 3.44e-06 | 1.15e-01 | 0.1067 |
| 83690 | CRISPLD1 | P49T-E | Human | Esophagus | ESCC | 3.38e-02 | 7.63e-01 | 0.1768 |
| 83690 | CRISPLD1 | P56T-E | Human | Esophagus | ESCC | 2.06e-02 | 7.10e-01 | 0.1613 |
| 83690 | CRISPLD1 | P57T-E | Human | Esophagus | ESCC | 7.58e-06 | 5.31e-01 | 0.0926 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00603242 | Esophagus | ESCC | face development | 34/8552 | 44/18723 | 1.90e-05 | 1.67e-04 | 34 |
| GO:00101711 | Esophagus | ESCC | body morphogenesis | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
| GO:00603253 | Esophagus | ESCC | face morphogenesis | 21/8552 | 28/18723 | 1.57e-03 | 7.33e-03 | 21 |
| GO:00603232 | Esophagus | ESCC | head morphogenesis | 22/8552 | 32/18723 | 7.12e-03 | 2.58e-02 | 22 |
| GO:00603244 | Thyroid | PTC | face development | 24/5968 | 44/18723 | 1.52e-03 | 8.49e-03 | 24 |
| GO:00603255 | Thyroid | PTC | face morphogenesis | 17/5968 | 28/18723 | 1.55e-03 | 8.63e-03 | 17 |
| GO:00101713 | Thyroid | PTC | body morphogenesis | 23/5968 | 43/18723 | 2.66e-03 | 1.35e-02 | 23 |
| GO:00603234 | Thyroid | PTC | head morphogenesis | 18/5968 | 32/18723 | 3.72e-03 | 1.79e-02 | 18 |
| GO:006032511 | Thyroid | ATC | face morphogenesis | 21/6293 | 28/18723 | 8.94e-06 | 8.95e-05 | 21 |
| GO:001017111 | Thyroid | ATC | body morphogenesis | 28/6293 | 43/18723 | 2.35e-05 | 2.06e-04 | 28 |
| GO:006032411 | Thyroid | ATC | face development | 28/6293 | 44/18723 | 4.39e-05 | 3.54e-04 | 28 |
| GO:006032311 | Thyroid | ATC | head morphogenesis | 22/6293 | 32/18723 | 5.14e-05 | 3.99e-04 | 22 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CRISPLD1 | SNV | Missense_Mutation | c.79N>G | p.Pro27Ala | p.P27A | Q9H336 | protein_coding | deleterious(0.02) | benign(0.057) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| CRISPLD1 | SNV | Missense_Mutation | rs566911502 | c.664N>T | p.Arg222Trp | p.R222W | Q9H336 | protein_coding | deleterious(0) | benign(0.2) | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CRISPLD1 | SNV | Missense_Mutation | novel | c.881N>A | p.Ser294Tyr | p.S294Y | Q9H336 | protein_coding | deleterious(0.01) | benign(0.438) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CRISPLD1 | SNV | Missense_Mutation | novel | c.1406N>T | p.Arg469Ile | p.R469I | Q9H336 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CRISPLD1 | SNV | Missense_Mutation | c.714N>A | p.Asn238Lys | p.N238K | Q9H336 | protein_coding | deleterious(0.02) | benign(0.41) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| CRISPLD1 | SNV | Missense_Mutation | rs566911502 | c.664N>T | p.Arg222Trp | p.R222W | Q9H336 | protein_coding | deleterious(0) | benign(0.2) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| CRISPLD1 | insertion | In_Frame_Ins | novel | c.162_163insCTGGTTCTGCGCGTACTGGCTGTACGGAGCAGGAGCAAG | p.Lys54_Arg55insLeuValLeuArgValLeuAlaValArgSerArgSerLys | p.K54_R55insLVLRVLAVRSRSK | Q9H336 | protein_coding | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| CRISPLD1 | SNV | Missense_Mutation | c.64N>T | p.Pro22Ser | p.P22S | Q9H336 | protein_coding | tolerated(0.45) | benign(0) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CRISPLD1 | SNV | Missense_Mutation | c.1484G>C | p.Arg495Thr | p.R495T | Q9H336 | protein_coding | deleterious(0.02) | benign(0.444) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CRISPLD1 | SNV | Missense_Mutation | rs200273072 | c.392N>T | p.Thr131Met | p.T131M | Q9H336 | protein_coding | tolerated(0.17) | possibly_damaging(0.853) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |